WATERTOWN, Mass., Jan. 24, 2024 /PRNewswire/ -- ZWI Therapeutics, Inc. (ZWI), a biotechnology company focused on the development of protein therapeutics using proprietary new polymers, announces a Series A financing, the appointment of pharmaceutical industry veterans Drs. Larry Miller and Ron Cohen as Independent Directors to the company's Board of Directors, and Dr.

马萨诸塞州沃特敦，2024年1月24日/PRNewswire/--ZWI Therapeutics，Inc.（ZWI），一家专注于使用专有新聚合物开发蛋白质治疗剂的生物技术公司，宣布了一系列融资，任命制药行业资深人士拉里·米勒（LarryMiller）博士和罗恩·科恩（RonCohen）博士为公司董事会独立董事。

Ed Mascioli as Chief Executive Officer and Board Director..

Ed Mascioli担任首席执行官兼董事。。

'After closing our Series A $10 million financing from Co-win Ventures and Sherpa Healthcare Partners, engaging such high caliber executives in our company is a testimony to the confidence successful entrepreneurs see in the ZWI technology. Ed Mascioli's significant experience leading multiple biotech companies is important in our Company's growth' said Dr.

“在完成了由合资企业和夏尔巴医疗保健合作伙伴提供的1000万美元A系列融资后，我们公司聘请了如此高素质的高管，这证明了成功企业家对ZWI技术的信心。埃德·马斯切利（EdMascioli）领导多家生物技术公司的丰富经验对我们公司的发展很重要。

Shaoyi Jiang, the Robert Langer '70 Family and Friends Professor at Cornell University, ZWI Board member, and co-founder. 'As board members, Ron and Larry collectively bring decades of successful pharmaceutical industry experience to ZWI. We will utilize their extensive expertise as ZWI advances its pipeline of wholly-owned and differentiated candidates that aim to tackle immunogenicity of protein therapeutics - a major challenge in biologics development' said Dr.

康奈尔大学罗伯特·兰格（RobertLanger）“70位亲朋好友”教授、ZWI董事会成员、联合创始人蒋绍义（ShaoyiJiang）作为董事会成员，罗恩和拉里共同为ZWI带来了数十年成功的制药行业经验。随着ZWI推进其全资和差异化候选产品渠道，我们将利用他们广泛的专业知识，以解决蛋白质治疗剂的免疫原性问题，这是生物制剂开发中的一个重大挑战。

Mascioli. ZWI created new polymers, based on polycarboxybetaine, with several advantages over polyethylene glycol (PEG), including reduced immunogenicity and preserved pharmacokinetics, and can be used on many protein therapeutics, lipid nanoparticles, and hydrogels. These novel polymers are supported by dozens of issued and pending patents and over 300 publications..

马西奥利。ZWI基于聚羧基甜菜碱创建了新的聚合物，与聚乙二醇（PEG）相比具有几个优点，包括降低免疫原性和保留药代动力学，可用于许多蛋白质治疗剂，脂质纳米粒子和水凝胶。这些新型聚合物得到了数十项已发布和正在申请的专利以及300多篇出版物的支持。。

ZWI's lead program, ZWI-001 (uricase-polycarboxybetaine conjugate), has demonstrated preclinical proof of concept and is currently in development to treat hyperuricemia in severe gout. ZWI has gained meaningful guidance on CMC, non-clinical, and clinical plans from the FDA via an INTERACT meeting and is progressing toward filing an IND..

ZWI的主要项目ZWI-001（尿酸酶-聚羧基甜菜碱缀合物）已经证明了临床前的概念证明，目前正在开发中，用于治疗严重痛风的高尿酸血症。ZWI通过INTERACT会议从FDA获得了关于CMC，非临床和临床计划的有意义的指导，并正在向IND提交进展。。

About ZWI Therapeutics, Inc.

关于ZWI Therapeutics，Inc。

ZWI, founded in 2020 by Drs. Bob Langer and Shaoyi Jiang, is a biotechnology company using a novel, patented polymer, polycarboxybetaine, to develop protein-polymer conjugates with potentially superior safety and efficacy over currently marketed therapeutics conjugated with polyethylene glycol (PEG).

ZWI由Bob Langer博士和Shaoyi Jiang博士于2020年成立，是一家生物技术公司，使用新型专利聚合物聚羧基甜菜碱开发蛋白质-聚合物偶联物，其安全性和有效性可能优于目前市场上与聚乙二醇（PEG）偶联的治疗剂。

I n preclinical animal models, polycarboxybetaine conjugates have demonstrated consistently low or no immunogenicity and excellent pharmacokinetics compared to PEG conjugates. These attributes are expected to translate to enhanced clinical durability and safety compared to pegylated drugs. The ZWI platform polymer technology is also broadly useful in the development of nanoparticles and hydrogels, the latter especially for cellular therapies.

在临床前动物模型中，与PEG缀合物相比，聚羧基甜菜碱缀合物始终表现出低或无免疫原性和优异的药代动力学。与聚乙二醇化药物相比，这些属性有望转化为增强的临床耐久性和安全性。ZWI平台聚合物技术也广泛用于纳米颗粒和水凝胶的开发，后者尤其适用于细胞疗法。

ZWI will out-license its technology to pharmaceutical companies for specific development programs. ZWI is headquartered in Waltham, MA, USA. For more information about ZWI platforms and pipeline, please visit www.zwitx.com, follow up on LinkedIn https://www.linkedin.com/company/zwitx or contact us at [email protected]..

ZWI将其技术授权给制药公司进行特定的开发计划。ZWI总部位于美国马萨诸塞州沃尔瑟姆。有关ZWI平台和管道的更多信息，请访问www.zwitx.com，关注LinkedInhttps://www.linkedin.com/company/zwitx或通过[电子邮件保护]联系我们。。

About Gout

关于痛风

Gout is diagnosed in 3.9% of the U.S. population- up to 13 million patients - and is the most common form of inflammatory arthritis. Gout is a serious, lifelong disease that needs ongoing treatment and requires changes in lifestyle habits to achieve control. If poorly treated, advanced gout can lead to the same level of work loss, physical disability, and diminished quality of life as is seen in advanced rheumatoid arthritis.

痛风在3.9%的美国人口中被诊断出来，多达1300万患者，是最常见的炎性关节炎。痛风是一种严重的终身疾病，需要持续治疗，需要改变生活习惯才能控制。如果治疗不当，晚期痛风可能导致与晚期类风湿性关节炎相同程度的工作损失，身体残疾和生活质量下降。

Gouty arthritis is caused by an accumulation of uric acid crystals in joints that causes severe pain, disfigurement and mobility restrictions. Uric acid crystals can also deposit in other tissues throughout the body, such as the kidney, which can lead to kidney stones, the skin (deposits called tophi) and even in vasculature walls.

痛风性关节炎是由关节中尿酸晶体的积累引起的，导致严重的疼痛，毁容和活动受限。尿酸晶体也可以沉积在整个身体的其他组织中，例如肾脏，这可能导致肾结石，皮肤（沉积物称为tophi）甚至血管壁。

Beyond pain and disability, deposition of uric acid crystals triggers the inflammatory cascade and contributes to well-known comorbidities, including thromboses, stroke, and major adverse cardiovascular events (MACE). Control of uric acid levels is the key to controlling gout and the inflammatory sequelae.

除了疼痛和残疾之外，尿酸晶体的沉积还会引发炎症级联反应，并导致众所周知的合并症，包括血栓形成，中风和主要不良心血管事件（MACE）。控制尿酸水平是控制痛风和炎症后遗症的关键。

Approximately 5-10% of patients, estimated at 250,000-400,000 people in the US, treated with oral urate lowering therapies do not respond adequately, and are termed refractory gout. Only one product is currently approved to treat refractory gout: KRYSTEXXA® (pegloticase, pegylated uricase). Refractory gout is an area of significant unmet medical need in a large market..

大约5-10%的患者（在美国估计有250000-400000人）接受口服降尿酸治疗后反应不佳，被称为难治性痛风。目前只有一种产品被批准用于治疗难治性痛风：KRYSTEXXA®（聚乙二醇化尿酸酶，聚乙二醇化尿酸酶）。难治性痛风是一个巨大市场中尚未满足的医疗需求领域。。

Ron Cohen, M.D. is President, CEO, and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the nervous system. Dr. Cohen previously was an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses.

医学博士罗恩·科恩是Acorda Therapeutics，Inc.的总裁、首席执行官和创始人，Acorda Therapeutics，Inc.是一家开发神经系统疾病治疗方法的公共生物技术公司。科恩博士之前是高级组织科学公司（Advanced Tissue Sciences，Inc.）的管理人员，该公司是一家生物技术公司，从事人体器官组织移植的生长。

Dr. Cohen serves on the Boards of ZWI Therapeutics and of the Biotechnology Innovation Organization (BIO). He is past Chair of the Board of BIO's Emerging Companies Section, and of the New York Biotechnology Association (NYBA). He is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region.

科恩博士是ZWI Therapeutics和生物技术创新组织（BIO）的董事会成员。他曾任生物技术新兴公司部董事会主席和纽约生物技术协会（NYBA）主席。他是纽约市首席执行官终身成就奖（NY CEO Life Achievement Award）和安永会计师事务所（Ernst&Young）纽约大都会区年度企业家奖（Enterpriser of the Year）的获得者。

He was named Neuroinvestment's CEO of the Year and is an inductee of the National Spinal Cord Injury Association's 'Spinal Cord Injury Hall of Fame'. Dr. Cohen has been recognized by the NYBA as the 'The Cures Start Here' Business Leader of the Year, by the Westchester County Association as its Leadership Award recipient, by Life Science Leader Magazine as True Life Science Leader of the Year, by PR Week/MM&M as one of the Health Influencer 50, by Scientific American as one of the 100 Most Influential People in Biotech, and by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry.

他被评为Neuroinvestment年度CEO，是美国国家脊髓损伤协会“脊髓损伤名人堂”的入选者。科恩博士被纽约市律师协会（NYBA）评为“the Cures Start Here”年度商业领袖，被韦斯特切斯特县协会（Westchester County Association）评为其领导力奖获得者，被《生命科学领袖杂志》（Life Science Leader Magazine）评为年度真正的生命科学领袖，被公共关系周/MM＆M评为健康影响力50强之一，被《科学美国人》（Scientific American）评为生物技术领域100位最具影响力的人物之一，并被PharmaVOICE杂志评为生物制药行业100位最具灵感的人之一。

Dr. Cohen received his B.A. degree from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine..

科恩博士在普林斯顿大学获得学士学位，在哥伦比亚医学院获得医学博士学位。他在弗吉尼亚大学医学中心完成了内科住院医师资格，并获得了内科委员会认证。。

Larry Miller, M.D. currently serves as the Chief Executive Officer and Board Chair of Apnimed, a private biotechnology company which he co-founded in 2017 to develop therapeutics to treat obstructive sleep apnea. Since 1991, Dr. Miller has founded or co-founded 10 life sciences/healthcare companies including Macrolide Pharmaceuticals, HPR, Avicenna, PharMetrics, ImpactRx, Serenex, Optio Research, Tetraphase, and Activate, and has served as CEO or Board member or both in each case.

医学博士拉里·米勒（LarryMiller）目前担任私人生物技术公司Apnimed的首席执行官和董事会主席，该公司于2017年共同成立，旨在开发治疗阻塞性睡眠呼吸暂停的疗法。自1991年以来，米勒博士创立或共同创立了10家生命科学/医疗保健公司，包括大环内酯类药物，HPR，Avicenna，PharMetrics，ImpactRx，Serenex，Optio Research，Tetraphase和Activate，并担任CEO或董事会成员或两者兼任。

Two of these companies completed public offerings and seven were acquired. Dr. Miller also co-founded the Mediphase funds, where he led investments in both private and public life sciences/healthcare companies, having served previously in a similar role at Hambrecht & Quist Capital Management. Dr. Miller received an A.B.

其中两家公司完成了公开募股，七家被收购。米勒博士还与他人共同创立了中期基金，他曾在Hambrecht＆Quist Capital Management担任类似职务，并在那里领导了对私人和公共生命科学/医疗保健公司的投资。米勒博士获得了A.B。

from Harvard College, an M.D. from Harvard Medical School, and completed clinical training in internal medicine and pulmonary disease at the Massachusetts General Hospital. He is Board certified in Internal Medicine, Pulmonary Disease, and Clinical Pharmacology..

来自哈佛大学，哈佛医学院医学博士，并在马萨诸塞州总医院完成了内科和肺部疾病的临床培训。他拥有内科、肺病和临床药理学的董事会认证。。

Ed Mascioli, M.D. has been CEO of multiple private biotech companies, successfully selling two. Prior to his role as CEO, Dr Mascioli was a Venture Partner at SV Life Sciences. Previously, Dr. Mascioli was at Pfizer where he established a new unit in rare, orphan, and genetic diseases with assets aggregated from both external to and within Pfizer in hemophilia, muscular dystrophy, hereditary emphysema, cystic fibrosis, and mucopolysaccharidoses.

医学博士Ed Mascioli曾担任多家私人生物技术公司的首席执行官，成功出售了两家公司。在担任首席执行官之前，Mascioli博士是SV生命科学公司的风险合伙人。此前，Mascioli博士曾在辉瑞公司（Pfizer）工作，在那里他建立了一个罕见，孤儿和遗传疾病的新部门，其资产从辉瑞公司内外聚集在血友病，肌肉萎缩症，遗传性肺气肿，囊性纤维化和粘多糖贮积症中。

Dr. Mascioli was also at MPM Capital, a leading healthcare venture capital firm with over $2.5B assets under management, where he led 10 financings totaling $299M, including new equity investments, bridge loans, and equity re-financings. Dr. Mascioli participated in the raising of two venture funds totaling $1.4B.

Mascioli博士还在MPM Capital任职，MPM Capital是一家领先的医疗风险投资公司，管理着超过25亿美元的资产，他领导了10次融资，总计2.99亿美元，包括新股权投资、过桥贷款和股权再融资。Mascioli博士参与了两项总计14亿美元的风险基金的筹集。

As the investor representative, Dr. Mascioli has served as a Director on the Boards of Arriva Pharmaceuticals, Elixir Pharmaceuticals, Mindset BioPharmaceuticals, and Oxagen, Ltd., and as an Observer on the Boards of CGI Pharmaceuticals, Radius Health, and Peptimmune. Dr. Mascioli started his career on the faculty of Harvard Medical School as an Assistant Professor of Medicine and on the staff of the Beth Israel Deaconess Hospital in Boston.

作为投资者代表，Mascioli博士曾担任Arriva Pharmaceuticals、Elixir Pharmaceuticals、Mindement BioPharmaceuticals和Oxagen，Ltd董事会董事，以及CGI Pharmaceuticals、Radius Health和Peptimmune董事会观察员。Mascioli博士的职业生涯始于哈佛医学院（Harvard Medical School）的医学助理教授和波士顿贝斯以色列女执事医院（Beth Israel Deaconess Hospital）的工作人员。

Dr. Mascioli holds an M.S. from MIT, an M.D. from the University of Massachusetts Medical School, and a B.A., cum laude, from Brandeis University..

Mascioli博士拥有麻省理工学院（MIT）的硕士学位、马萨诸塞大学医学院（University of Massachusetts Medical School）的医学博士学位以及布兰代斯大学（Brandeis University）的学士学位。。

Co-win Ventures was founded in 2009 and is a top-tier China headquartered venture capital firm with a global vision to invest in high-tech and healthcare industries. With over USD 950 million under management to date, it has invested in more than 130 private companies with about half of them already exited through IPOs and M&A.

合作共赢风险投资公司成立于2009年，是一家总部位于中国的顶级风险投资公司，具有投资高科技和医疗保健行业的全球视野。迄今为止，该公司管理着超过9.5亿美元的资金，已经投资了130多家私营公司，其中约一半已经通过IPO和并购退出。

Co-win has won multiple national and world-renowned venture capital awards. With professional teams based in China and the US, Co-Win becomes seeks to become a long-term partner for portfolio start-ups, assisting in building their companies, integrating industrial resources, and navigating with strategic insights..

Co-win获得了多个国家和世界知名的风险投资奖项。凭借在中国和美国的专业团队，Co-Win Been寻求成为投资组合初创公司的长期合作伙伴，协助建立公司，整合行业资源，并以战略眼光进行导航。。

Sherpa Healthcare Partners was founded in 2018 by financiers who previously worked together in one of China's leading venture capital firms where they built and led its professional medical investment team, including setting up and leading investments in a dedicated healthcare fund. The founders have been teamed together in close co-operation, built on shared values, mutual trust, and complementary capabilities.

Sherpa Healthcare Partners由金融家于2018年成立，他们之前曾在中国领先的风险投资公司之一合作，在那里建立并领导其专业的医疗投资团队，包括建立和领导专门的医疗基金投资。创始人紧密合作，建立在共享价值观、相互信任和互补能力的基础上。

Sherpa has now become an influential healthcare VC firm in the industry..

夏尔巴现在已成为业内有影响力的医疗保健风险投资公司。。

SOURCE ZWI Therapeutics

来源ZWI Therapeutics